Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672530 | 0.84 | DRD2 (0.56) | DRD2DRD4DRD3KMT2AALDH1A1 | |
| SCHEMBL254817 | 0.83 | MCL1 (0.61) | NQO1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL1548013 | 0.83 | KDM4E (0.58) | NQO1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL5673992 | 0.81 | DRD2 (0.57) | DRD2DRD4DRD3HPGDKDM4E | |
| SCHEMBL143430 | 0.80 | NQO1 (0.59) | NQO1DRD2DRD4DRD3KMT2A | |
| SCHEMBL4500324 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3KMT2AALDH1A1 | |
| SCHEMBL13744660 | 0.79 | GAA (0.56) | KMT2AALDH1A1HPGDKDM4EGAA | |
| SCHEMBL3786617 | 0.79 | NQO1 (0.52) | NQO1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL2322205 | 0.79 | NQO1 (0.46) | NQO1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL29957289 | 0.79 | NQO1 (0.46) | NQO1KMT2AALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2021257834-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3416962-B1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI SA (FR) | 2021-05-05 | — | — | EP | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3611166-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3524600-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS | Sanofi (FR) | 2019-08-14 | — | — | EP | disclosed |
| US-20170233340-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9714221-B1 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2017-07-25 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080009506-A1 | Imidazole Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | US | disclosed |
| US-20080009506-A1 | Imidazole Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | NQO1 3853/4885DRD2 850/4885DRD4 1490/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | NQO1 2856/4885DRD2 733/4885DRD4 973/4885 |
| US-20080009506-A1 | Imidazole Compound | KCNH2, KCNJ2, KCNH3 | NQO1 3141/4885DRD2 1867/4885DRD4 2677/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | NQO1 3642/4885DRD2 247/4885DRD4 306/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | NQO1 3144/4885DRD2 94/4885DRD4 207/4885 |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | KCNJ2, KCNJ1, KCNJ11 | NQO1 2225/4885DRD2 1150/4885DRD4 1461/4885 |
| US-20170233340-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | NQO1 248/4885DRD2 1097/4885DRD4 1245/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NQO1 2962/4885DRD2 371/4885DRD4 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.